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area covered by microglia which may compromise immune 
protection and, therefore, neuronal survival. In vitro experi-
ments demonstrated that soluble fractions (extracellular/cyto-
solic) from AD hippocampi were toxic for microglial cells. 
This toxicity was abolished by AT8 and/or AT100 immuno-
depletion, validating that soluble phospho-tau was the toxic 
agent. These results were reproduced using soluble fractions 
from phospho-tau-positive Thy-tau22 hippocampi. Cultured 
microglial cells were not viable following phagocytosis of 
SH-SY5Y cells expressing soluble intracellular phospho-tau. 
Because the phagocytic capacity of microglial cells is highly 
induced by apoptotic signals in the affected neurons, we pos-
tulate that accumulation of intraneuronal soluble phospho-tau 
might trigger microglial degeneration in the AD hippocam-
pus. This microglial vulnerability in AD pathology provides 
new insights into the immunological mechanisms underlying 
the disease progression and highlights the need to improve 
or develop new animal models, as the current models do not 
mimic the microglial pathology observed in the hippocampus 
of AD patients.
Keywords Alzheimer · Microglia · Pathology · Human 
brain · Hippocampus
Introduction
Alzheimer’s disease (AD) is so far an incurable, progres-
sive degenerative brain disorder characterized by the pres-
ence of extracellular amyloid-beta (Abeta) plaques and 
intracellular aggregated phosphorylated tau, together with 
synaptic and neuronal cell loss. Neuroinflammation has 
been postulated to be a critical factor in the pathogenesis of 
AD [16, 17, 19]. The microglial activation process is char-
acterized by remarkable morphological changes (larger cell 
Abstract The role of microglial cells in the development and 
progression of Alzheimer’s disease (AD) has not been eluci-
dated. Here, we demonstrated the existence of a weak micro-
glial response in human AD hippocampus which is in contrast 
to the massive microglial activation observed in APP-based 
models. Most importantly, microglial cells displayed a promi-
nent degenerative profile (dentate gyrus > CA3 > CA1 > par-
ahippocampal gyrus), including fragmented and dystrophic 
processes with spheroids, a reduced numerical density, and 
a significant decrease in the area of surveillance (“microglial 
domain”). Consequently, there was a substantial decline in the 
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body with shorter, thicker, and less branched processes) and 
up-regulation of proinflammatory and/or anti-inflammatory 
cytokines [13, 18, 44]. Activated microglia accumulate 
around Abeta plaques in both transgenic models [18, 22, 
44] and AD patients [49, 50]. Although the inflammatory 
response could contribute to Abeta phagocytosis [11, 20], 
it has been associated with a neurotoxic detrimental effect 
mediated by the release of proinflammatory cytokines/
chemokines and neurotoxins [16, 17, 19].
The inflammatory response in the AD brain is prob-
ably not exclusively detrimental or beneficial. In fact, 
recent human genome-wide association studies (GWAS) 
have identified multiple polymorphisms associated with 
the microglial immune response in AD [14, 24]. One such 
polymorphism, R47H, is located in TREM2 and is associ-
ated with an increased risk for late-onset AD [26]. TREM2 
is a lipid sensor that, through its adapter molecule DAP12, 
supports Abeta-reactive microgliosis and Abeta clearance 
[63]. In the absence of TREM2, microglial activation is 
impaired. In the 5xFAD mouse model, TREM2 deficiency 
increased Abeta accumulation due to a dysfunctional 
microglial response and microglia was apoptotic instead of 
activated [63]. Thus, a deficient rather than an overactive 
microglial response could, indeed, be associated with AD 
development [54].
The microglial response has been preferentially studied 
in AD brain areas with relatively high Abeta content or in 
Abeta-rich transgenic models [16, 22, 49–51]. However, 
brain regions particularly relevant in AD development, such 
as the hippocampal formation, present low Abeta accumu-
lation and a high number of phospho-tau-bearing neurons 
[4]. Thus, the microglial reaction in the hippocampus could 
be totally different than that previously described in neo-
cortical areas. In the present work, we evaluated the micro-
glial response in postmortem hippocampal human tissue 
pathologically diagnosed in Braak II to Braak V–VI stages. 
Contrary to the marked microglial activation reported in 
APP-based mice models and in human neocortical AD 
regions, we demonstrated a prominent degenerative pro-
cess of the microglia in the dentate gyrus (DG) and CA3 
of Braak V–VI samples, probably associated with the accu-
mulation of soluble phospho-tau, as determined by in vitro 
assays. This degenerative process left most of the affected 
regions with no immunological coverage and could con-
tribute to AD pathology progression.
Materials and methods
Human samples
Human autopsy specimens from the medial temporal lobe 
(hippocampal/parahippocampal regions) were obtained 
from the tissue bank Fundación CIEN (BT-CIEN; Cen-
tro de Investigación de Enfermedades Neurologicas; 
Madrid, Spain) and from the Neurological Tissue Bank of 
IDIBELL-Hospital of Bellvitge (Barcelona, Spain). The 
utilization of postmortem human samples was approved 
by the corresponding biobank ethics committees and by 
the “Comite de Etica de la Investigacion (CEI), Hospital 
Virgen del Rocio,” Seville, Spain. All cases were scored for 
Braak tau pathology. Table 1 summarizes the demographics 
of the human samples. Only Braak V–VI cases were clini-
cally classified as demented (AD) patients. We considered 
the age-matched Braak II individuals as controls in our 
experiments.
For morphological studies, 4 % paraformalde-
hyde fixed samples were sectioned (30 µm thickness) 
on a freezing microtome. For molecular characteriza-
tion, unfixed frozen samples were used. The anatomi-
cal boundaries of the hippocampal system and parahip-
pocampal gyrus were identified by the anatomical and 
Table 1  Human sample information
Braak stage Gender Age (years) (mean age ± SD) Postmortem delay (mean hours ± SD)
Male (%) Female (%)
(a) Unfixed frozen samples
 0 (n = 8) 62.5 37.5 49 ± 6 8 ± 5
 II (n = 13) 61.54 38.46 78 ± 8.5 7 ± 4
 III–IV (n = 9) 44.44 55.56 80 ± 11 6 ± 5
 V–VI (n = 18) 38.89 61.11 79 ± 10 8 ± 4
(b) Fixed samples
 0 (n = 4) 50 50 53 ± 16 7 ± 5
 II (n = 7) 28.6 71.4 78 ± 8.5 6 ± 3
 III–IV (n = 10) 50 50 79 ± 7 10 ± 5
 V–VI (n = 16) 43.8 56.20 78 ± 10 9 ± 5
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cytoarchitectonic features in sections stained with cresyl 
violet using a human stereotaxic brain atlas [30]. Areas 
between the bregma coordinates at 17 and 35 mm were 
analyzed.
Antibodies
The following primary antibodies were used: (1) mono-
clonals, anti-phospho-tau AT100 (pSer212/Thr214) and 
AT8 (pSer202/Thr205, Thermo Fisher Scientific, New 
York, USA), anti-total tau (tau46, Cell Signaling Tech-
nology, Massachusetts, USA), 4G8 (anti-Abeta 17-24, 
Biolegend, San Diego, USA), 6E10 (anti-Abeta1-16, 
Covance, Princeton, USA), 82E1 (anti-Abeta-N-termi-
nal, IBL, Hamburg, Germany), and anti-CD68 (PG-M1, 
Dako, Glostrup, Denmark); (2) rabbit polyclonals, anti-
amyloid fibrils (OC, Merck Millipore, Darmstadt, Ger-
many), anti-CD45 (Abcam, Cambridge, United King-
dom), anti-Iba1 (Wako Pure Chemical Industries, Osaka, 
Japan), and anti-P2ry12 (Sigma-Aldrich, Saint Louis, 
USA).
Immunohistochemistry
Sections from control and diseased brains were assayed 
simultaneously using the same batches of solutions to 
minimize variability in immunolabeling conditions. 
After antigen retrieval (80 °C for 20 min in 50 mM cit-
rate buffer, pH 6.0), endogenous peroxidase was inhibited 
(3 % H2O2/10 % methanol in PBS, pH 7.4 for 20 min) 
and non-specific staining was avoided using 5 % goat or 
horse serum (Sigma-Aldrich) in PBS. For single labeling 
light microscopy, sections were incubated with the pri-
mary antibody (24–72 h, at room temperature) followed 
by the corresponding biotinylated secondary antibody 
(1:500 dilution, 1 h at room temperature, Vector Labora-
tories), streptavidin-conjugated horseradish peroxidase 
(1:2000, 90 min, Sigma-Aldrich), and visualized with 
0.05 % 3-3-diaminobenzidine tetrahydrochloride (DAB, 
Sigma-Aldrich) and 0.01 % hydrogen peroxide in PBS. 
The specificity of the immune reactions was controlled by 
omitting the primary antisera. For double or triple immu-
nofluorescence labeling, sections were sequentially incu-
bated with the indicated primary antibodies followed by 
the corresponding Alexa 488/568/405 secondary antibod-
ies (1:1000 dilution, Invitrogen). AT100-immunolabeled 
sections were stained with 0.1 % thioflavin-S (Sigma-
Aldrich) in 70º ethanol for 10 min. Sections were incu-
bated in an autofluorescence eliminator reagent (Merck 
Millipore) following the manufacturer’s recommendations 
and examined under a confocal laser microscope (Leica 
SP5 II).
Stereological analysis
The number of Iba1-immunopositive microglial cells was 
stereologically quantified according to the optical frac-
tionator method [43] using an Olympus BX61 microscope 
equipped with the NewCAST software package (Olympus, 
Denmark). Cell counting was performed on every 6th sec-
tion (with a distance of 180 µm) through the rostrocaudal 
axis of the hilar region (n = 5–6 sections/individual). The 
dentate gyrus boundaries were defined using a 2× objec-
tive. Cell number was counted using a 100×/1.35 objective. 
We used a counting frame of 1722 µm2 with step lengths 
of 131.23 µm. The numerical density (cells/mm3) was esti-





, where ‘Q’ is the number of 
disector-counted somatic profiles, ‘
∑
A’ is the area of the 
counting frame, and ‘h’ is the section thickness (30 µm).
Image analysis
Microglial loading was defined as the percentage of area 
stained with anti-Iba1 (total microglia) or anti-P2ry12 (non-
activated microglia) in relation to the total area analyzed. 
Digital images (2 sections/individual) were processed using 
the Visilog 6.3 image analysis system (Noesis, France). The 
Iba1- or P2ry12-immunopositive signal within the selected 
brain region was converted into 8-bit gray scale, and immu-
nostained cells were identified by a threshold level mask. 
A fixed threshold level (ranging 160–180) was maintained 
throughout the image analysis of all sections from the same 
individual brain for uniformity. Microglial spatial distribu-
tion was determined by the grid analysis [3]. The dentate 
gyrus was photographed and processed with the Visilog 6.3 
program. Digital images (4×, 2 sections/individual, n = 5–8 
individuals per group) were binarized, and grid analysis 
was performed by placing a grid (354 × 354 μm/square) 
of 125,000 μm2 squares. The hilar region was divided into 
30–50 regular squares, covering the total parenchymal 
space. The microglial spatial distribution was then estimated 
by measuring the Iba1-positive coverage area in each square 
of the grid. Microglial domain was defined as the area (µm2) 
covered by a single P2ry12-positive cell. This area was 
calculated by drawing a polygon connecting the distal end 
of total branches of the cell (see Fig. 3c). Microglia cells 
(20–30 cells per section) from Braak II and Braak V–VI 
sections (2 sections/individual, n = 5–7 individuals) were 
randomly selected using stereology-based sampling (New-
CAST software from Olympus) and imaged under a 40× 
objective. The optical disector was set at 7118.3 µm2 with 
step lengths of 238.64 µm. Only microglial cells with a vis-
ible cell body were photographed. Finally, high-resolution 
images were processed using the Visilog 6.3 program, and 
the P2ry12-positive cell domain area was measured.
900 Acta Neuropathol (2016) 132:897–916
1 3
Transgenic animals
Animal experiments were performed in accordance 
with the Spanish and the European Union regulations 
(RD53/2013 and 2010/63/UE) with the approval of the 
Committees of Animal Research from the Universities of 
Seville (Spain) and Malaga (Spain). APP/PS1 and Thy-
tau22 transgenic animals were used. The APP/PS1mice 
[22, 58] over-expressed the human mutant PS1M146L and 
human APP751 carrying the Swedish (KM670/671NL) and 
London (V717I) mutations. The Thy-tau22 mice expressed 
human 4-repeat tau with G272 V and P301S mutations 
[48]. Non-transgenic mice (WT) of the same genetic back-
ground (C57/BL6) were used as controls. In this work, we 
used 2-, 6-, 9- and 12-month-old APP/PS1 mice; 2-, 9-, 
12- and 16-month-old Thy-tau22; and age-matched WT 
mice (n = 5/age and genotype). Mice were killed (sodium 
pentobarbital, 60 mg/kg) and processed as described [22, 
58]. Fixed brains were serially sectioned (40 µm coronal 
sections) and assayed for immunohistochemistry. Micro-
glial (Iba1-positive) loading and microglial domain were 
calculated as described above (7–9 sections/mouse; n = 4/
age/genotype).
Preparation of soluble S1 fractions and sequential 
protein extraction
Soluble S1 fractions from either mouse models or human 
samples were prepared as described [23]. Briefly, human or 
mouse tissue was homogenized (Dounce homogenizer) in 
TBS (20 mM Tris–HCl, 140 mM NaCl, pH 7.5) contain-
ing protease and phosphatase inhibitors (Roche). Homoge-
nates were ultracentrifuged (4 °C for 60 min) at 100,000×g 
(Optima MAX Preparative Ultracentrifuge, Beckman 
Coulter). Supernatants, S1 fractions, were aliquoted and 
stored at −80 °C. The pellets (P1) were extracted in RIPA 
buffer (1 % CHAPS, 1 % Na-deoxycholate, 0.2 % SDS, 
140 mM NaCl, 10 mM Tris–HCl, pH 7.4); ultracentrifuged 
and supernatants, S2 fractions (intracellular particulate 
proteins), were aliquoted and stored. Pellets (P2) were re-
extracted in buffered-SDS (2 % SDS in 20 mM Tris–HCl, 
pH 7.4, 140 mM NaCl), centrifuged as above and super-
natants, S3 (SDS releasable proteins) were stored. Finally, 
the remaining pellets were extracted in SDS-urea (20 mM 
Tris–HCl, pH 7.4, 4 % SDS and 8 M urea).
Sarkosyl‑insoluble fraction isolation
Sarkosyl-insoluble tau was isolated as described [29]. 
Human hippocampi were homogenized in “homogeniza-
tion buffer” (10 mM Tris, 0.8 M NaCl, 1 mM EGTA, 10 % 
sucrose, pH 7.4, plus protease, and phosphatase inhibitors). 
After centrifugation (5,000×g, 4 °C, 15 min), superna-
tants were incubated (2.5 h at 37 °C in agitation) with 1 % 
Sarkosyl (Sigma-Aldrich) and 1 % beta-mercaptoethanol 
(Sigma-Aldrich) in “homogenization buffer.” Samples were 
then ultracentrifuged (100,000×g, 4 °C, 30 min). Super-
natants constituted the Sarkosyl soluble fractions, whereas 
pellets were the Sarkosyl-insoluble fraction. The insoluble 
fraction was rinsed twice and resuspended in TBS.
Abeta and Tau quantification by sandwich ELISA
Total soluble Abeta or tau in S1 fractions was determined 
using a commercial sandwich ELISA (human Abeta x-40, 
Invitrogen; Abeta x-42, DRG; human Tau, Invitrogen) fol-
lowing the manufacturer’s recommendations. For each 
assay, 25 μg of protein from the pooled-soluble fractions 
were used. The ELISA experiments were repeated four 
times in independent experiments using triplicate replicas.
Total RNA and protein extraction
Total RNA and proteins were extracted using TriPure Isola-
tion Reagent (Roche) [22]. RNA integrity (RIN) was deter-
mined by RNA Nano 6000 (Agilent). Although no differ-
ences between Braak groups were observed, the RIN was 
lower in human samples compared with transgenic models 
(RIN: 4.95 ± 1.4 or 8.5 ± 0.5 for human and mouse sam-
ples, respectively). RNA was quantified using NanoDrop 
2000 spectrophotometer (Thermo Fischer). Proteins were 
quantified using Lowry’s method.
Retrotranscription and quantitative real‑time RT‑PCR
Retrotranscription (RT) (4 μg of total RNA) was performed 
with the High-Capacity cDNA Archive Kit (Applied Bio-
systems). For real-time qPCR, 40 ng of cDNA were mixed 
with 2× Taqman Universal Master Mix (Applied Biosys-
tems) and 20× Taqman Gene Expression assay probes 
(Applied Biosystems, supplemental Table 1). Quantita-
tive PCR reactions (qPCR) were done using an ABI Prism 
7900HT (Applied Biosystems). The cDNA levels were 
determined using GAPDH and beta-actin. We observed 
a highly significant linear correlation between the cycle 
threshold (Ct) of both genes (beta-actin vs GAPDH, 
r = 0.912, F(1,46) = 157.73, p < 0.0001). Thus, normali-
zation using either beta-actin or GAPDH produced identi-
cal results. Routinely, we used GAPDH as housekeeper. 
Results were expressed using the comparative double-delta 
Ct method (2-ΔΔCt). ΔCt values represent GAPDH nor-
malized expression levels. ΔΔCt was calculated using 
Braak 0 for human samples or 9-month-old WT mice for 
transgenic models.
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Western blots
Western blots were performed as previously described [22, 
23]. Abeta peptides were detected after 16 % SDS-Tris-Tri-
cine-PAGE using PVDF membranes (Immobilon-P Trans-
fer Membrane, Millipore) and a mixture of 6E10 (1/6000) 
and 82E1 (1/5000) antibodies. For Tau (Tau46, AT8 or 
AT100, 1/1000), proteins were loaded on 4–20 % SDS-
Tris–Glycine-PAGE (Bio-Rad) and transferred to nitrocel-
lulose (Optitran, GE Healthcare Life Sciences). Dot blots 
using OC were performed as previously described [22].
Cell cultures
BV2 microglial cells were grown (37 °C and 5 % CO2) 
in RPMI 1640, 2 mM glutamine, 10 % (v/v) fetal bovine 
serum, plus penicillin/streptomycin (all from Biowest). 
SH-SY5Y neuronal cells (SH-control cells) were grown in 
DMEM-F12, 2 mM glutamine, 10 % fetal bovine serum, 
penicillin/streptomycin, and 1 % non-essential amino acids 
(Biowest). SH-SY5Y-Tau (SH-tau cells, see [8]) stably 
transfected neuronal cells (expressing 3R human tau) were 
selected using G418 (0.2 µg/ml, Biowest). For co-culture 
experiments, BV2 cells were plated (15.000 cells/cm2, 
12 h) and SH-SY5Y cells were added at a ratio of 1/2.5 
(SH-SY5Y/BV2 cells). Cells were co-cultured for 12 h in 
RPMI 1640. After co-culture, the cells were detached by 
trypsin and analyzed by flow cytometry. Apoptosis of SH-
SY5Y cells (either control or tau-expressing cells) was 
induced using 1 µg/ml staurosporine B (Sigma-Aldrich) 
for 2 h [25]. This short treatment produced 72 ± 5.7 % of 
apoptotic SH-SY5Y cells. The absence of any direct effect 
of staurosporine B on BV2 cells was analyzed by omitting 
the SH-cells. Primary murine microglial or astroglial cul-
tures were performed as previously described [22].
BV2 treatment with S1 soluble fractions
BV2 cells (15.000 cells/cm2) were serum deprived for 
12 h and then treated (0.1 µg soluble protein/µl of culture 
medium) for 12 h with soluble S1 fractions (from Braak 0 
to V–VI or transgenic mice models). The effect on the cell 
survival was assessed by flow cytometry.
Flow cytometry analysis of cell viability and apoptosis
The viability and apoptosis of BV2 cells were assessed 
using the apoptosis detection kit Annexin V-FITC (Immu-
nostep) following the manufacturer’s specifications and 
were analyzed using a FACSCanto II flow cytometer (BD 
Services, San Jose, CA, USA). The pro-apoptotic effect 
of SH-SY5Y cells on BV2 cultures was evaluated by dou-
ble staining the cells with CD45-PE (BV2) and Annexin 
V-FITC (apoptosis). Control experiments using single cell 
cultures (either viable or apoptotic BV2 or SH-SY5Y) were 
conducted to determine the discrimination settings (CD45-
positive (BV2) and -negative (SH-SY5Y) cells). With this 
protocol, 86 ± 2.3 % of viable BV2 cells were discrimi-
nated from SH-SY5Y cells. Control experiments also dem-
onstrated that a fraction (16 ± 4.3 %) of apoptotic BV2 
cells displayed a reduction in the expression of CD45 and 
cannot be distinguished from SH-SY5Y cells.
BV2 and SH‑SY5Y phagocytosis assay (TAMRA assay)
Phagocytosis was assessed by loading SH-SY5Y or SH-
SY5YTau cells with 5 µM TAMRA-ester (5-(and-6)-car-
boxytetramethylrhodamine succinimidyl ester, Sigma-
Aldrich) [12]. TAMRA-loaded SH-cells were then treated 
(2 h) with staurosporine (1 µg/ml of culture medium; apop-
totic cells) or PBS (control cells) and co-cultured with BV2 
microglia (1/2.5 SH- vs BV2). Phagocytic BV2 cells were 
identified by CD45-PE and TAMRA fluorescence. For the 
inhibition of phagocytosis, cytochalasin B (5 μg/ml) was 
added to culture 30 min prior the experiment and main-
tained throughout the assay.
Statistical analysis
Normality of data was assessed using the Kolmogorov–
Smirnov test. Normally distributed data were expressed as 
the mean ± SD. Non-normally distributed data were rep-
resented using box-plots (Sigmaplot) or scatter-plots with 
the median and interquartile range (GraphPad). For nor-
mally distributed data, mean values were compared using 
ANOVA followed by Tukey’s test (more than two groups) 
or two-tailed t test (for two group comparisons). The data 
which were not normally distributed were compared by 
the Mann–Whitney U test (for two groups comparisons) or 
Kruskal–Wallis tests (more than two groups) followed by 
Dunn’s post-hoc test. The significance was set at 95 % of 
confidence. Linear correlations were analyzed using the 
Kendall tau-beta test. In all the cases, IBM SPSS (v23) Sta-
tistics software was used.
Results
Weak activation and marked degeneration of microglial 
cells in the AD hippocampus
We first evaluated the activation status of microglial cells 
from human samples by qPCR and surprisingly, markers 
as CD11b, Iba1, TREM2 and CD33 were not significantly 
altered in AD patients (Fig. 1a, a3–6). Only the expres-
sion of CD45 and CD68 was significantly increased in the 
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Braak V-VI samples (Fig. 1a, a1–2). In addition, a signifi-
cant increase in the expression of C/EPB-alpha and Pu.1 
genes was also found (supplemental Fig. 1a, a1-2). Moreo-
ver, we observed significant linear correlations between the 
expression of all four markers (CD45, CD68, Pu.1 and C/
EPBa), implying the existence of a unique cell population 
(supplemental Fig. 1a, a3-6). Microglial activation was 
also tested by immunohistochemistry using Iba1 (Fig. 1b). 
Morphologically, Iba1-positive cells in Braak II tissue dis-
played a highly ramified profile, consistent with a non-acti-
vated phenotype (Fig. 1b, b1–4). The presence of activated 
microglia (enlarged cell body and thickened and retracted 
branches) was very scarce in Braak III-IV tissue (not 
shown) and slightly more abundant in Braak V–VI tissue 
(Fig. 1b, b5–8). These cells were exclusively observed sur-
rounding Abeta plaques, as also assessed using CD45 and 
CD68 markers (Fig. 1c). This limited microglial activation 
was in agreement with the low and late presence of extra-
cellular Abeta deposits in the hippocampus (supplemental 
Fig. 1c) [4], while substantial phospho-tau accumulation 
was broadly distributed in the hippocampal formation in 
the Braak V–VI stage tissue (supplemental Fig. 1b). On the 
other hand, in Braak V–VI samples, an apparent low num-
ber of Iba1-positive microglial cells was observed (com-
pare Fig. 1b, b1–2 and b5–6).
We next assessed the percentage of area occupied by 
the microglial cells immunostained for the P2ry12 receptor 
(P2ry12 loading). As shown here (Fig. 2a, a1–a4), P2ry12-
positive microglia were abundant in Braak II samples, dis-
playing a highly ramified morphology. Significant regional 
differences with dentate gyrus > CA3 > CA1 > parahip-
pocampal gyrus (PHG) were observed (Kruskal–Wallis, 
p = 0.002, p < 0.05 Dunn’s post-hoc test) (Fig. 2a). How-
ever, microglial cells exhibited a remarkable pathology in 
Braak V–VI samples (Fig. 2a, a5–a8). At the dentate gyrus 
and CA3 (Fig. 2a, a5–6), microglia were notably scarce and 
displayed clear morphological abnormalities (see Fig. 3b 
for details), whereas those in the CA1 and PHG appeared 
less affected (Fig. 2a, a7–8). This observation was quantita-
tively confirmed (Fig. 2a, a9–12). The quantitative analysis 
of the Braak III–IV samples (images not shown) showed a 
highly heterogeneous pattern.
The reduction in P2ry12-microglial loading could actu-
ally reflect a decrease in the total microglial population in 
AD samples or a down-regulation of the P2ry12 receptor 
following microglial activation (see supplemental Fig. 2a 
and also Ref. [5]). Thus, we next evaluated the area occu-
pied by Iba1-positive microglial cells. As shown in Fig. 2b, 
we observed a similar pattern as above. In Braak II samples, 
highly ramified microglia were abundant with loads higher 
in the DG and CA3 than in the CA1 or PHG (Fig. 2b, b1–4; 
Kruskal–Wallis p = 0.009, p < 0.05 Dunn’s post-hoc test). 
Furthermore, Braak V–VI samples also showed a reduction 
in Iba1-positive microglial cell number and/or arborization 
(Fig. 2b, b5–8). Indeed, this observation was quantitatively 
corroborated (Fig. 2b, b9–12). Also in agreement with our 
previous data, Braak III–IV samples (not shown) displayed 
an intermediate pathology between Braak II and Braak V–
VI samples. Thus, both microglial markers, P2ry12 and 
Iba1, gave similar results. In addition, we also observed a 
highly significant linear correlation between both P2ry12 
and Iba1 levels in both the DG and CA3 (Kendall τ correla-
tion analysis; τ = 0.50, p = 0.0001).
Microglial pathology in the AD hippocampus includes 
reduced cell number, dystrophic morphology, reduced 
area of surveillance of individual cell, and altered 
spatial distribution
We next focused on the hilar region of the dentate gyrus, 
as it was the most affected hippocampal region, and quan-
tified the numerical density (cells/mm3) of Iba1-positive 
cells using stereology (Fig. 3a). The data demonstrated no 
differences between the Braak II and Braak III–IV cohorts 
with relative constant numerical density among individu-
als (Fig. 3a, a5). However, Braak V–VI cases displayed 
two different populations. Four of the nine cases presented 
a clear decrease in the Iba1-positive microglial number 
(Figs. 3a, a3–5), whereas the other five individuals exhib-
ited similar numbers to those in the Braak II cases, mak-
ing the difference statistically non-significant. However, we 
did observe clear morphological differences between Braak 
II and Braak V–VI stages in all analyzed cases (Fig. 3b). 
Compared with Braak II (Fig. 3b, b1 and b7), Braak V–VI 
cases with (1) a low number of microglial cells (Fig. 3b, 
b2–3 or b8–9 for Iba1 and P2ry12, respectively), (2) an 
intermediate number of microglial cells (Fig. 3b, b4 and 
b10 for Iba1 or P2ry12, respectively), or (3) no reduction 
in microglial cells (Fig. 3b, b5–6 or b11–12 for Iba1 and 
Fig. 1  Attenuated microglial activation in the hippocampus of AD 
brains (Braak V–VI). a Microglial activation was analyzed (qPCR) in 
Braak 0 (n = 8) and age-matched Braak II (n = 13), Braak III–IV 
(n = 9) and Braak V–VI (n = 17) cases. Expression levels, normal-
ized using GAPDH, were referenced to Braak 0. The data are rep-
resented individually (dots) or as box-plots. Significance was ana-
lyzed by Kruskal–Wallis and Dunn’s multiple comparison tests. b 
Iba1-immunostained sections of Braak II (b1–4) and Braak V–VI 
(b5–8) tissue. Morphological evaluation showed microglial pathology 
in Braak V–VI individuals (b5–6). c High magnification images of 
Braak V–VI microglial cells immunostained for CD68 (c1) and CD45 
(c2). Activated microglia were predominantly observed forming clus-
ters of cells surrounding Abeta plaques (blue in c5) as demonstrated 
by triple (Iba1 in red/CD45 in green/Abeta in blue) immunofluores-
cence and confocal microscopy (c3–5). Alv alveus, g granular layer, 
h hilus, m molecular layer, so stratum oriens, slm stratum lacunosum-
moleculare; sp stratum pyramidale, sr stratum radiatum. I–VI cortical 
layers. Scale bars b1–8, 500 µm (insets in b4 and b8, 20 µm); c1–2, 
25 µm; c3–5, 10 µm
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P2ry12, respectively) exhibited an abnormal morphol-
ogy, even though the extent and severity of the microglial 
pathology varied among the individuals. The pathology 
was characterized by shortened and less branched pro-
cesses that usually were deformed, displaying cytoplasmic 
abnormalities (including spheroids) and even fragmentation 
(cytorrhexis), although this could be due to pathological 
redistribution of the microglial markers (see also Refs. [54, 
57]).
The observed microglial pathology could also be 
reflected by a reduction in the microglial domain, the area 
of surveillance of an individual microglia. To quantitatively 
address this possibility, we measured the area covered by 
individual P2ry12-positive microglial cells selected by an 
unbiased stereological approach (see methods). We used 
the anti-P2ry12 antibody, because it produced better immu-
nostaining of the thin and small microglial processes. As 
mentioned above, the expression of this purinergic recep-
tor also decreased upon activation. Thus, only areas dis-
tant from plaques were included in the study. As shown in 
(Fig. 3c, c5), there was a severe decrease in the microglial 
domain in Braak V–VI compared with Braak II individu-
als. In fact, the microglial domain was drastically reduced 
from 2012.12 ± 453.44 μm2 per cell (n = 200 cells from 
5 Braak II individuals) to 1119.39 ± 376.86 μm2 per cell 
(n = 300 cells from 7 Braak V–VI individuals; Mann–
Whitney U test, p = 0.0001).
The partial decrease in the microglial counts (cells/
mm3), the abnormal morphology of the cells, and the 
drastic reduction in the microglial domain clearly dem-
onstrated the existence of prominent microglial pathology 
in the dentate gyrus of Braak V–VI samples. Therefore, 
this extensive microglial pathology could also produce 
a reduction in the parenchymal space protected by these 
immune cells. To assess this possibility, we estimated 
the spatial distribution of microglial cells in the DG. 
As shown in Fig. 4a (a1–2 and a5–6), microglial cells 
from Braak II samples showed a regular spatial distri-
bution, homogeneously covering the DG. This regular 
organization was reflected by a normal distribution of 
the area (Iba1-positive area) covered by the microglia 
(Fig. 4a, a6). These data agree well with those previously 
described (see Figs. 1, 2, 3) and indicate that microglial 
cells from aged Braak II patients were resting/non-acti-
vated. However, the same analysis in Braak V–VI sam-
ples demonstrated the existence of a clear reduction in 
the parenchymal area covered by the microglial cells in 
the hilus of the DG (Fig. 4a, a3–4 and a5–6). This reduc-
tion was not due to the migration and concentration of 
microglial cells around Abeta plaques, with the conse-
quent depletion from adjacent areas, as demonstrated by 
the clear shift in the distribution curve to a lower covered 
area (Fig. 4a, a6). In fact, the area covered by microglial 
cells was reduced from 0.24 ± 0.06 μm2/μm2 of paren-
chymal space (n = 4) to 0.08 ± 0.04 μm2/μm2 of paren-
chymal space (n = 9; Mann–Whitney U test p = 0.012) in 
Braak II and Braak V–VI samples, respectively. Notably, 
in the most severely affected Braak V–VI hippocampi, 
microglial cells were no longer even associated with the 
neuritic plaques (Fig. 4b, b2 and b4) or with the vascu-
lar amyloid (Fig. 4b, b1–3), highlighting the extent of the 
microglial alterations.
The high heterogeneity of the microglial pathology 
observed in Braak III–IV individuals is also noteworthy 
(see Fig. 4a, a5–6). Compared with the Braak II popula-
tion, three cases (from a total of five analyzed) displayed a 
significant decrease (Kruskal–Wallis p = 0.0001, p < 0.05 
Dunn’s post-hoc test) in the area covered by microglial 
cells, whereas the other two cases were identical to the 
Braak II group. Although the number of cases studied was 
limited, the heterogeneous microglial pathology detected in 
these experiments was also consistent with the P2ry12 and 
Iba1 loads (see Fig. 2).
The microglial degeneration of AD patients is not 
reproduced by transgenic mice
The microglial pathology in the Braak V–VI samples was 
in clear contrast to the intense microglial response in most 
APP-based transgenic models [16, 22]. Thus, we directly 
compared the microglial response in the hippocampus 
of our APP/PS1 model. As expected [22], we observed a 
massive accumulation of Abeta plaques and Abeta pep-
tides (supplemental Fig. 3a, a1–2). This accumulation was 
associated with a strong microglial reaction (supplemen-
tal Fig. 3a, a3–6) characterized by a patent increase in the 
expression of most tested microglial genes (supplemental 
Fig. 3a, a7). The active microglial cells were mainly located 
surrounding the Abeta plaques (supplemental Fig. 3a, a3-6). 
A marked microglial activation was observed in the hilus 
of the dentate gyrus (supplemental Fig. 3a, a3, a5) along 
with a significant increase in the Iba1-positive microglial 
Fig. 2  Reduced microglial load in Braak V–VI hippocampus. Micro-
glial pathology was assessed using P2ry12 receptor (a) and Iba1 (b) 
immunostaining. a Representative images of Braak II (a1–4) and 
Braak V–VI (a5–8) samples in different hippocampal areas (indicated 
in the figure). Quantitative analysis (a9–12) of the area of paren-
chymal space (percentage) occupied by P2ry12-positive microglial 
cells in Braak II (n = 5; orange circles), Braak III–IV (n = 6; light-
green squares), and Braak V–VI (n = 7; dark green triangles) sam-
ples. The results are shown individually (dots) with the median and 
the interquartile range. b Representative images from different hip-
pocampal areas of Braak II (b1–4) and Braak V–VI (b5–8) samples 
immunostained for Iba1. Quantitative analysis (b9–12) of Iba1 load 
(percentage) determined in the same population as in panels a9–12. 
*p = 0.03; **p = 0.005, Mann–Whitney U test comparison between 
Braak II and Braak V–VI groups. Scale bars a1–8 and b1–8, 50 µm
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loading even at relatively early ages (6–9-month-old APP/
PS1) (supplemental Fig. 3a, a8).
As mentioned above (supplemental Fig. 1b-c), the tau 
pathology in the human AD hippocampi was significantly 
more prominent than the Abeta accumulation. Thus, we 
also tested the microglial response in the Thy-tau22 model 
[48] (supplemental Fig. 3b). Thy-tau22 hippocampi accu-
mulated phosphorylated tau protein principally in the CA1 
pyramidal cells (supplemental Fig. 3b, b1-2). Similar to 
human samples, microglial cells in this transgenic model 
displayed a limited activation (supplemental Fig. 3b, b3-5). 
Only the expression of CD45, CD68, and TREM2 seemed 
to be slightly elevated in these mice (compare supplemen-
tal Figs. 3b, b5 and 3a, a7). Furthermore, this model also 
presented an attenuated microglial pathology, characterized 
by a reduction in the microglial arborization (supplemental 
Fig. 3b, b3-4) with a consequent significant decrease in the 
microglial domain (supplemental Fig. 3b, b6). Therefore, 
although attenuated, the microglial pathology in this tau 
model could resemble the Braak V–VI cases.
In sum, our data demonstrated the existence of a local 
degenerative process of the microglial cells in the AD hip-
pocampus that was not mimicked by Abeta models and 
only partially by tau models.
Soluble phospho‑tau induces toxicity in microglial cells 
in vitro
We next investigated the factor(s) involved in microglial 
degeneration. Of the multiple possible factors, we focused 
on Abeta and phospho-tau as the major toxic proteins in 
AD. Furthermore, we hypothesized that soluble Abeta and/
or phospho-tau would be implicated in this degenerative 
process. Thus, hippocampal samples were fractionated into 
soluble (S1, comprising both extracellular and cytosolic 
proteins) [23]), compartmentalized (S2, including intracel-
lular vesicular content), aggregated (S3, SDS releasable 
pool), and highly aggregated (P3, Urea plus SDS releas-
able pool) fractions (see supplemental Fig. 4 for a detailed 
description).
Quantitative analysis of S1 fractions (Fig. 5a) dem-
onstrated the preferential accumulation of soluble AT8 
(Fig. 5a, a1–2) and AT100 (Fig. 5a, a3–4) phospho-tau in 
the Braak V-VI group. With the exception of a single Braak 
III–IV case (from 9 cases tested), the presence of phospho-
tau in the cytosolic/extracellular soluble S1 fraction was 
exclusively detected in AD samples. However, the total 
soluble tau levels were similar between the different groups 
(supplemental Fig. 4a, a2). The Abeta content of these sam-
ples was low, as previously reported [23].
We next evaluated, in vitro, whether these soluble S1 
fractions were toxic for BV2 microglial cells. Pooled-
soluble fractions (0.1 μg of soluble protein/μl of culture 
media) from Braak 0 (6 individuals), Braak II (10 individu-
als), and Braak III–IV samples (9 individuals) produced no 
appreciable toxicity on BV2 cells (Fig. 5b, b1–2). Approxi-
mately 90 % of BV2 cells remained viable after treatment. 
However, under the same experimental conditions, pooled 
S1 fractions from Braak V–VI samples (12 individuals) 
produced a strong toxic effect on BV2 cells. After 12 h of 
incubation, we observed a highly significant increase in 
early and late-apoptotic cells and only 1.0 ± 0.7 % (n = 6 
independent experiments) of cells remained viable (Fig. 5b, 
b1–2). This effect was dose-dependent (not shown), and, in 
fact, the Braak V-VI S1 fractions presented a highly toxic 
potency (EC50 = 0.009 ± 0.007 μg/μl; n = 3). Soluble 
fractions from Braak 0, Braak II, or Braak III–IV had no 
effect in the range tested (from 0.1 ng to 0.1 μg of S1 pro-
tein per microliter of culture media).
To assess whether soluble Abeta or phospho-tau was 
the potential toxic agent, Braak V–VI derived S1 frac-
tions were immunodepleted with either 6E10 + 82E1 (total 
Abeta) or AT8, AT100, and AT8 + AT100 (phospho-tau 
depletion) antibodies. The treatment with 6E10 + 82E1 
antibodies produced absolutely no reduction on the toxicity 
of the S1 fractions (Fig. 5b, b3–4). However, AT8, AT100, 
and the combination of both antibodies produced a partial 
(for either AT8 or AT100 antibodies) or a complete sup-
pression (for the combination of AT8 and AT100 antibod-
ies) of the S1 toxicity on BV2 cells (Fig. 5b, b3–4).
It could be argued that this toxic effect was non-spe-
cific and simply reflects the toxicity of soluble proteins 
from Braak V–VI brain samples. To test this possibility, 
Fig. 3  Microglial degeneration at the dentate gyrus of the Braak 
V–VI hippocampus. a Numerical density (cells/mm3) of Iba1-posi-
tive microglia at the hilar region from Braak II (a1, boxed area a2; 
n = 5), Braak III–IV (not shown; n = 5), and Braak V–VI (a3, boxed 
area a4; n = 9) cases was determined by stereology. Sections were 
immunostained with anti-Iba1 and counterstained with cresyl violet. 
The data (a5) are shown individually or by box-plot. b Representative 
high magnification images of Iba1 (b1–6) and P2ry12 (b7–12) immu-
nostained microglial cells from Braak II (b1 and b7) and Braak V–VI 
cases with (b2–3 and b8–9) or without (b4–6 and b10–12) differences 
in the numerical density. Abnormal morphological features of micro-
glial cells were visualized with both Iba1 (b1–6) and P2ry12 (b7–12) 
immunostaining and included deramification (b2 and b8), fragmenta-
tion (b3 and b9), beading with spheroidal swellings (b4–5 and b10–
11), shortening (b5–6 and b10–11), and dystrophies (b6 and b12) of 
the processes. c Microglial domain (area of surveillance of a single 
microglial cell; c2 and c4) was quantitatively determined (c5) in the 
dentate gyrus of Braak II (n = 5) and Braak V–VI (n = 8) cases. 
P2ry12-positive cells were randomly selected using stereology-based 
sampling (n = 200 or 300 cells from Braak II or Braak V–VI cases). 
Quantitative data (dot plots and median plus interquartile range) 
demonstrated the existence of a highly significant decrease (Mann–
Whitney U test, p = 0.00001) in the microglial domain in Braak V–
VI samples, compared with age-matched Braak II cases. DG dentate 
gyrus, g granular layer, h, hilus, m molecular layer. Scale bars a1 and 
a3, 500 µm; a2 and a4, 100 µm; b1–b12, 20 µm; c1 and c3, 50 µm; c2 
and c4, 20 µm
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we performed several control experiments. First, we 
tested whether aggregated Sarkosyl-insoluble phospho-tau 
(supplemental Fig. 5a, a1) was also toxic for BV2 cells. 
However, this phospho-tau fraction produced absolutely no 
toxicity (supplemental Fig. 5a, a2-3). Second, soluble frac-
tions prepared from APP/PS1 transgenic models, despite 
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the relatively high oligomeric Abeta content (supplemen-
tal Fig. 6a, a1) and the strong microglial activation (sup-
plemental Fig. 3a, see above and [22]), produced no reduc-
tion in BV2 viability (supplemental Fig. 6a, a2). Third, in 
accordance with the putative toxic effect of soluble phos-
pho-tau, aged transgenic Thy1-tau22 mice accumulated 
soluble phospho-tau (AT8-positive) in the S1 fractions 
(supplemental Fig. 6b, b1), and, consequently, the S1 frac-
tions from these mice produced a significant reduction in 
the number of viable BV2 cells (supplemental Fig. 6b, b2). 
Notably, S1 fractions isolated from younger tau transgenic 
animals (2 and 9 months of age) showed lower levels of 
AT8-positive tau and produced no effect on BV2 viability 
(supplementary Fig. 6b, b2). Fourth, this effect was not a 
general cytotoxic effect produced by soluble phospho-tau, 
as demonstrated by the absence of a toxic effect of Braak 
V-VI-derived S1 fractions on the astroglial cell line WJE 
(supplemental Fig. 5b, b1-2) and primary murine astro-
glial cultures (not shown). Finally, a similar toxic effect 
of S1 fractions from Braak V–VI samples was also repro-
duced in murine primary microglial cells (viable cells 
66.10 ± 16.12; 58.69 ± 6.39 and 15.46 ± 6.64 %, for PBS, 
Braak II and Braak V–VI, respectively; n = 3 for PBS or 
n = 5 for Braak II and V–VI; ANOVA F(2,10) = 55.06, 
p = 0.0001; Tukey p < 0.05). Therefore, these data demon-
strated that soluble phospho-tau, present predominantly in 
Braak V-VI samples, was pro-apoptotic for microglial cells 
in vitro.
As mentioned above, the S1 fractions contained both 
extracellular and cytosolic soluble proteins. Thus, although 
the existence of extracellular tau is now considered cru-
cial for AD propagation [1, 9, 56], phospho-tau could be 
predominantly accumulated in the cytosol. Therefore, it 
is likely that most of the phospho-tau in our S1 fractions 
were originally located intraneuronally. However, it is also 
known that microglia cells could phagocytose apoptotic 
tau-bearing neurons [29, 35]. Thus, we also tested whether 
intracellular phospho-tau could be toxic for microglia after 
phagocytosis. For these experiments, we co-cultured BV2 
cells with SH-SY5Y cells constitutively expressing 3R 
human tau (SH-tau cells). These SH-tau cells accumulated 
soluble intracellular phospho-tau (supplemental Fig. 6c). 
Non-transfected SH-SY5Y cells were used as control cells 
(SH-control cells).
First, we evaluated whether BV2 microglial cells 
(CD45-positive cells) were able to phagocytose apop-
totic SH-controls cells. In fact, control experiments using 
TAMRA-loaded viable or apoptotic SH-control cells 
demonstrated BV2 actively phagocytosed apoptotic cells 
(TAMRA-positive BV2 cells: 7.5 ± 3.5 vs 70.2 ± 4.66 % 
in presence of control and apoptotic SH-cells, respectively, 
n = 3, see also [12]). Second, we tested whether phagocy-
tosis of SH-control cells was toxic for BV2 microglia. Our 
data demonstrated that phagocytosis of SH-control cells 
was not toxic for BV2 cells. As shown in Fig. 6a (a1–2), 
co-culture of viable (75.7 ± 5.1 % viable cells, n = 4) or 
apoptotic (72 ± 5.7 % apoptotic cells, n = 4) SH-cells pro-
duced low or non-toxicity on BV2 microglial cells. Moreo-
ver, co-culture of viable (84.7 ± 4.5 % viable cells, n = 6) 
SH-tau-cells were also non-toxic for BV2 cells (Fig. 6a, 
a1–2). Thus, the phagocytic process of staurosporine-
induced apoptotic cells was not toxic for BV2 cells, and, 
furthermore, the presence of intracellular soluble phospho-
tau in viable neuronal cells, such as SH-tau, was also not 
toxic for microglia. However, co-incubation of BV2 cells 
with apoptotic SH-tau cells (79.3 ± 8.4 % of apoptotic 
cells, n = 6) produced a clear toxic effect on this microglial 
cell line (Fig. 6a, a1–2). In fact, 43.55 ± 8.18 % (n = 6; 
ANOVA F(5,20) = 36.33, p = 0.0001, Tukey p < 0.05) of 
BV2 cells were annexin V-positive under these conditions. 
Therefore, phagocytosis of phospho-tau-bearing apoptotic 
cells seemed to be toxic for microglia.
The implication of active phagocytic activity in the 
toxic process was also probed by the physical inhibition of 
phagocytosis using a transwell device. As shown in Fig. 6a 
(a1–2), the inclusion of apoptotic SH-tau-cells into the tran-
swell completely prevented BV2 toxicity. Furthermore, the 
pharmacological inhibition of phagocytosis, using cytocha-
lasin B (from 79.96 ± 2.25 to 25.3 ± 1.15 % of phago-
cytic BV2 cells, using the TAMRA assay, n = 3), pro-
duced a significant inhibition in BV2 toxicity induced by 
apoptotic SH-tau-cells (62.63 ± 4.47 vs 36.00 ± 3.41 %, 
n = 4; in the absence or in the presence of cytochalasin 
B, respectively; two-tailed t test t = 9.38, p = 0.0001). As 
an additional control experiment, we also tested whether 
Abeta-accumulating neuronal cells, such as N2a-APPswe 
cells [58, 61], were toxic after phagocytosis. As expected, 
Fig. 4  Significant reduction in the parenchymal area covered by 
microglial cells in the Braak V–VI dentate gyrus. a Microglia were 
immunostained using anti-Iba1, and cells were counterstained with 
cresyl violet (a1, a3, representative Braak II and Braak V–VI cases). 
The binarized images were overlaid with a grid of 30–50 regular 
squares (354 × 354 mm/square; a2 and a4) covering the total hilar 
area of the dentate gyrus. The space covered (μm2) by microglial 
cells (Iba1-positive) was determined in each square (40–60 squares 
per sample; Braak II n = 4; Braak III–IV n = 5; Braak V–VI n = 9) 
and is individually represented in a5 (n = 137, 182 or 320 individual 
squares for Braak II, III–IV, and V–VI, respectively). The data were 
analyzed by Kruskal–Wallis and Dunn’s multiple comparison tests. 
Significance difference between groups is indicated in the figure. 
(a6) Relative frequency distribution of each individual was calculated 
using IBM SPSS, and the average (±SD) is shown in the figure. b 
Representative Braak V–VI cases showing Abeta and either vascular 
(b1 and b3) or parenchymal deposits (b2 and b4) lacking microglial 
coverage. The sections were double immunostained using 4G8 (dark 
blue) and Iba1 (brown) antibodies. DG dentate gyrus, g granular 
layer, h hilus, m molecular layer. Scale bars a1, a3 and b1, 500 µm; 
b2 and b3, 100 µm; b4, 25 µm
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co-culture of viable or apoptotic N2a-APPswe cells did 
not produce toxicity on BV2 microglia (11.38 ± 0.34 vs 
11.31 ± 3.51 %, n = 4, for viable or apoptotic N2a-APPswe 
cells, respectively). Therefore, either extracellular (through 
a possible direct effect) or intracellular (through a phago-
cytic process) phospho-tau was toxic for microglial cells, 
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whereas soluble Abeta seemed to have a little to no effect 
under these conditions. This hypothesis is in agreement 
with the multiple microscopic images displaying microglial 
cells surrounding and, probably, phagocytosing neurofibril-
lary tangle-bearing neurons (Fig. 6b, b1–3) and tau-positive 
neuropil threads (Fig. 6b, b4–6) in the hippocampus of the 
Braak V–VI samples.
In conclusion, the release of soluble phospho-tau species 
or the phagocytosis of neurons containing soluble phospho-
tau produced a toxic effect on microglial cells.
Discussion
The role of the inflammatory response in Alzheimer’s dis-
ease is far from elucidated. In this study, we evaluated the 
microglial response in the hippocampus of postmortem 
human samples classified from Braak 0 to Braak VI stages. 
Contrary to the expected results based on APP-transgenic 
models [16, 22, 33], an attenuated rather than massive 
microglial activation was observed in Braak V–VI samples 
(AD cases). More importantly, the present results also dem-
onstrate the existence of a microglial degenerative process 
in the Braak V–VI hippocampus. This degenerative pro-
cess was more prominent in the hilar region of the dentate 
gyrus and the CA3 region of the hippocampus proper. The 
microglial pathology is characterized by the following: (1) 
the presence of degenerative microglial cells, which exhibit 
shortened and less branched processes, cytoplasmic frag-
mentation (cytorrhexis) and spheroids formation (see also 
[54, 57]); (2) a reduction (at least in 4 of 9 Braak V–VI 
cases tested) in the microglial numerical density; and (3) a 
dramatic decrease in the area of surveillance of individual 
microglial cells, described here as the microglial domain. 
These pathological modifications produce a prominent 
decrease in the parenchymal area covered by microglia 
in these particular hippocampal subfields (DG and CA3), 
leaving most of the parenchymal space with no immune 
coverage, including Abeta plaques and vascular Abeta 
depositions.
It could be argued that this microglial degenerative pro-
cess reflects the advanced pathological status of demented 
Braak V–VI individuals. If this is the case, we speculate 
that non-demented cases with lower pathology (Abeta and/
or tau accumulation), such as Braak II or Braak III–IV 
samples, could better reflect the early microglial response 
[47]. However, microglial cells from Braak II individuals 
presented a highly ramified morphology with a regular spa-
tial distribution, covered the total parenchymal space, and 
displayed absolutely no signs of activation or degeneration. 
Furthermore, neither molecular nor morphological evalu-
ation of the Braak III–IV samples indicated the existence 
of microglial activation outside of that restricted to Abeta 
plaques or vascular deposits. Concerning microglial degen-
eration, Braak III–IV samples were highly heterogeneous. 
Approximately 50 % of the tested Braak III–IV population 
displayed similar morphological and molecular parameters 
to that of the Braak II population, whereas the other 50 % 
better resembled the Braak V–VI cases (see Figs. 2, 4). We 
do not know what determines this heterogeneity. However, 
the existence of a highly significant correlation between 
two different microglial markers, P2ry12 and Iba1, in 
both the DG and CA3 subfields from samples of different 
Braak pathology (from Braak II to Braak V–VI individuals) 
strongly suggests that the microglial degeneration in Braak 
V–VI patients, at these particular hippocampal areas, could 
be part of a continuum along with the progression of the 
AD.
As mentioned above, microglial degeneration was par-
ticularly evident in the hilus of the dentate gyrus and in the 
CA3 subfield. Interestingly, these two hippocampal areas 
also displayed the highest microglial loading compared 
with other hippocampal subfields in Braak II individuals. 
Although we do not know what determines this microglial 
regionalization, it is obvious that the higher microglial load 
in Braak II samples and the microglial degeneration in AD 
patients seem to be associated with the DG-CA3 connec-
tion by the mossy fibers. In this sense, recent studies have 
suggested the existence of hippocampal hyperexcitability 
in both AD patients [2] and transgenic models [40, 60]. 
This hyperactive status is particularly evident at the level of 
DG to CA3 connection. Although we cannot conclude that 
a hyperactive status of the mossy fibers is involved in the 
microglial degeneration observed in AD patients based on 
the present data, this idea could be a potential explanation, 
and further investigation is clearly needed.
Fig. 5  Soluble phospho-tau from the Braak V–VI hippocampus was 
toxic for cultured microglial cells. a Representative AT8 (a1) and 
AT100 (a3) western blots of soluble S1 fractions (extracellular/cyto-
solic) isolated from Braak 0 (n = 6), Braak II (n = 8), Braak III–IV 
(n = 8), or Braak V–VI (n = 8) individuals. GAPDH (lower panel 
in a3) was used as the loading control. The relative abundance of 
AT8 (a2) or AT100 (a4) phospho-tau proteins (approximately 55 kDa 
band) was determined by the densitometry analysis. The data were 
normalized by Braak 0 samples and are shown individually or as 
box-plots. Significance was determined by Kruskal–Wallis and Dunn 
tests. b BV2 microglial cells were incubated with S1 fractions from 
Braak 0 to V–VI samples. Toxicity was analyzed by flow cytometry. 
(b1) Representative Annexin V/propidium iodide (PI) double stain-
ing of BV2 cells treated with S1 fractions. (b2) Quantitative analysis 
of cell viability after S1 treatment. (b3 and b4) Representative flow 
cytometry experiments and quantitative analysis of BV2 cells treated 
with Braak V–VI derived S1 fractions that were sham-depleted, 
Abeta-depleted (6E10 plus 82E1), AT8-depleted, AT100-depleted, 
and AT8 and AT100-depleted. In all cases, the S1 fractions were incu-
bated with identical amounts of protein G-Sepharose. The data (b2 
and b4) are shown as the mean ± SD of six different experiments. 
Significance (indicated in the figure) was determined by ANOVA and 
Tukey post-hoc test
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Fig. 6  Phagocytosis of apoptotic SH-SY5Y cells expressing human 
tau was toxic for BV2 cells. a Flow cytometry analysis of BV2 apop-
tosis (CD45- and Annexin V-positive cells) induced after co-culture 
with viable or apoptotic SH-control or SH-tau cells. (a1) Representa-
tive double staining of CD45/Annexin V BV2 cells co-cultured with 
viable (left panels) or apoptotic (right panels) SH-SY5Y cells (SH-
control; upper panel), SH-SY5Y cells transfected with Tau (SH-tau; 
middle panel), and SH-tau cells co-cultured into a transwell device 
(lower panel). (a2) Quantitative analysis of apoptotic BV2 cells 
(percentage) selected by CD45 and Annexin V double staining. The 
number of independent experiments was indicated in the figure. The 
data are shown as the mean ± SD. Significance (indicated in the fig-
ure) was determined by ANOVA and Tukey post-hoc test. b Repre-
sentative Braak V–VI hippocampus images with double Iba1 and AT8 
immunofluorescence and laser confocal microscopy showing micro-
glial cells in very close contact with phospho-tau-positive neuronal 
somata (b1–3) or neuropil threads (b4–6) suggestive of microglial-
mediated phagocytosis of affected neurons. Scale bar 20 µm
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The implication of microglial cells in the development 
of neurodegenerative disorders is generally accepted [16, 
19, 59]. However, microglial dysfunction in AD has been 
primarily associated with over-activation and cytotoxic-
ity of these cells [19, 59]. Microglial activation has been 
undoubtedly observed in cerebral regions with the early 
and abundant extracellular Abeta deposits [15, 36, 49, 50]. 
In fact, microgliosis has been associated with the disease 
duration and the neurodegenerative progression of AD 
[49–51]. Furthermore, in the APP-based transgenic mod-
els, microglial activation may drive the AD pathology. In 
this sense, increases in microglial reactivity [32] or, in con-
trast, pharmacological depletion of microglial cells [32, 
36, 53, 63] clearly enhanced or reduced Alzheimer’s dis-
ease pathology, respectively, with consequent changes in 
tau phosphorylation, synaptic strength, and neuronal cell 
lost. Therefore, the data presented here seem to contradict 
those previously reported. The most parsimonious explana-
tion to reconcile these, apparently, contradictory observa-
tions is the different Abeta and/or tau content between dif-
ferent brain regions in AD patients and/or animal models. 
Most of these observations are based on Abeta producing 
mice, similar to our APP/PS1 model, or in Abeta-rich corti-
cal areas from AD patients. However, the hippocampus of 
AD patients exhibits low and late Abeta pathology, whereas 
phospho-tau accumulates starting in the early stages of the 
disease [4]. Thus, the preferential accumulation of phos-
pho-tau over Abeta plaques could induce a totally different 
microglial response.
The pathological consequence(s) of a deficient immu-
nological protection due to the microglial degeneration 
observed in AD patients are unknown. Microglial cells are 
implicated in the maintenance of synaptic integrity [62] 
and, in fact, could promote learning-dependent synaptic 
formation [41]. In addition, microglia is involved in Abeta 
phagocytosis [27, 64, 65], senile plaque compaction, and 
limitation of Abeta toxicity [7, 66]. Furthermore, micro-
glia play a relevant role in removing damaged neurons and 
neuronal components, such as aberrant synaptic terminals 
or demyelinated axons. In this sense, deficiencies in key 
genes for microglial survival and/or proliferation (such as 
CSF1R or TREM2) are associated with rare hereditary neu-
rodegenerative diseases, such as adult-onset leukoencepha-
lopathy with axonal spheroids or Nasu–Hakola disease 
(respectively) [6, 38, 39]. In both diseases, the microglial 
response and, more relevant, the microglial survival seem 
to be compromised. Moreover, the rs75932628 polymor-
phism results in an R47H missense mutation in TREM2 
and increases the risk for late-onset AD [14, 26, 37, 65]. 
Furthermore, TREM2 knock-out models display dystrophic 
microglial cells similar to that described in this work [42], 
deficiencies in microglial survival, and aggravation in AD 
pathology [63, 65]. Although the presence of any of these 
rare TREM2 variants in our limited AD cohort is highly 
improbable, these studies together with our present data 
strongly suggest that microglial pathology, with the conse-
quent deficient immunoprotection in relatively large areas 
of the hippocampus, such as the dentate gyrus and CA3, 
might, indeed, contribute to the progression of AD pathol-
ogy and cognitive impairment.
Another relevant finding of our work is the demonstra-
tion of the toxic effect of soluble intra- and/or extracellular 
phospho-tau on microglial cells by in vitro assays, which 
strongly supports the hypothesis that phosphorylated tau 
is the putative toxic agent for microglia in the AD hip-
pocampus. Furthermore, our in vitro experiments are also 
in concordance with the differential microglial response to 
the Abeta or phospho-tau pathology observed in transgenic 
models and with the neuroprotection observed in tau-defi-
cient models [31, 45]. However, we are also aware that the 
microglial pathology in the tau model was modest and less 
obvious than what was observed in the Braak V–VI sam-
ples. We do not know why this apparent discrepancy exists, 
and it clearly indicates that AD pathology is more complex 
than what is reproduced in mouse models.
We do not know which form(s) of phospho-tau (mono-
meric vs oligomeric) exerts the toxic effect on microglial 
cells. However, it is important to emphasize that not all 
phospho-tau species present in AD samples are toxic for 
microglial cells, as demonstrated using Sarkosyl-insoluble 
phospho-tau. It has long been recognized that Sarkosyl-
insoluble phospho-tau is part of the intracellular paired 
helical filaments that constitute the basis for neurofibril-
lary tangle formation [28]. Therefore, as proposed by oth-
ers, tangle formation could represent a cellular protec-
tion mechanism that prevents neuronal toxicity [46] and, 
as probed in this work, microglial toxicity. The cause of 
the accumulation of soluble phospho-tau species in AD 
patients is currently unknown.
Another open question is whether soluble phospho-tau 
is released by the neurons or, on the contrary, is retained 
intracellularly. Although there is evidence that supports the 
neuronal release of tau [1, 9, 10, 56], our data also demon-
strate that soluble intracellular phospho-tau could be toxic 
for microglia after phagocytosis. The phagocytic capacity 
of microglial cells is highly induced by apoptotic signals in 
the affected neurons [34, 52]. Thus, we postulate that not 
only the accumulation of intraneuronal soluble phospho-
tau but also the induction of apoptosis and the consequent 
phagocytosis of the phospho-tau affected neurons by the 
microglia trigger the toxicity in these cells, although the 
exact intracellular/extracellular cell death mechanism needs 
to be further investigated. Supporting this suggestion, via-
ble SH-tau cells produced no toxicity, whereas apoptotic 
tau-expressing SH-cells were highly toxic for BV2 cells. 
Moreover, phagocytosis of Abeta-expressing N2a-APPswe 
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cells was not toxic for microglial cells. Furthermore, the 
toxic effect was suppressed by physical (transwell device) 
and pharmacological (cytochalasin B) inhibition of phago-
cytosis. Therefore, the toxic effect of soluble phospho-tau 
in AD cases is likely mediated by the microglial phagocytic 
capacity for the clearance of apoptotic tau-bearing neu-
rons or, more probably, for the elimination of the neuropil 
threads. This suggestion is in agreement with a recent work 
[21] that demonstrates the involvement of microglia in the 
phagocytosis of synapses after oligomeric Abeta stimula-
tion and the accumulation of soluble phospho-tau in the 
presynaptic terminals of demented cases [55]. Thus, based 
on these observations, we postulate that the accumulation 
of soluble phospho-tau forms in aberrant synaptic termi-
nals and/or dystrophic neurites could induce the phagocytic 
response of the microglial cells, thereby producing toxicity 
in these cells. This close association between tau-bearing 
neurons or neuropil threads and severely dystrophic micro-
glial cells has also been reported by Streit and co-workers 
[54].
This restricted toxic effect, together with a probably 
limited regenerative capacity of the microglial cells in AD 
individuals, could explain the regional pattern of micro-
glial degeneration and also the minor microglial pathology 
observed in other hippocampal regions, such as CA1 or 
CA2, with a high accumulation of tangle-bearing neurons.
In summary, our results demonstrate the existence of 
a significant microglial degenerative process in the hip-
pocampus of AD patients. This degenerative process 
reduces the parenchymal area covered by microglia and 
consequently compromises the immune coverage and 
neuronal survival. Our data also demonstrate that soluble 
AT8- and/or AT100-positive phospho-tau species, located 
either extracellular or intracellular after phagocytosis, 
drive microglial degeneration. The microglial vulnerability 
in AD pathology provides new insights into the immuno-
logical mechanisms underlying this neurodegenerative dis-
ease. Finally, our findings highlight the need to improve or 
develop new animal models, as the current models do not 
mimic the microglial pathology observed in the hippocam-
pus of AD patients.
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